Virus inactivation (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Virus inactivation" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

5web.archive.org

1^st place

1^st place

2^nd place

2^nd place

5^th place

5^th place

low place

low place

1semanticscholar.org

11^th place

8^th place

low place

low place

low place

low place

1asahi-kasei.co.jp

low place

low place

low place

low place

1nybloodcenter.org

low place

low place

18^th place

17^th place

asahi-kasei.co.jp (Global: low place; English: low place)

"Planova: Home". Asahi-kasei.co.jp. 2010-07-29. Archived from the original on 2010-01-29. Retrieved 2010-11-23.

doi.org (Global: 2^nd place; English: 2^nd place)

Shander A, Lobel GP, Javidroozi M (June 2016). "Transfusion practices and infectious risks". Expert Review of Hematology. 9 (6): 597–605. doi:10.1586/17474086.2016.1164593. PMID 26959944. S2CID 36732554.
Elveborg S, Monteil V, Mirazimi A (2022-02-19). "Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes". Pathogens. 11 (2): 271. doi:10.3390/pathogens11020271. ISSN 2076-0817. PMC 8879476. PMID 35215213.
Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Güertler L, Ironside JW (January 2016). "Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders". Blood Reviews. 30 (1): 35–48. doi:10.1016/j.blre.2015.07.004. PMC 7115716. PMID 26381318.
Kim NA, Kar S, Li Z, Das TK, Carpenter JF (September 2021). "Mimicking Low pH Virus Inactivation Used in Antibody Manufacturing Processes: Effect of Processing Conditions and Biophysical Properties on Antibody Aggregation and Particle Formation". Journal of Pharmaceutical Sciences. 110 (9): 3188–3199. Bibcode:2021JPhmS.110.3188K. doi:10.1016/j.xphs.2021.06.002. ISSN 0022-3549. PMID 34090901.

eurodia.com (Global: low place; English: low place)

"Nanofiltration". Eurodia.com. Archived from the original on 2011-07-10. Retrieved 2010-11-23.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Kim NA, Kar S, Li Z, Das TK, Carpenter JF (September 2021). "Mimicking Low pH Virus Inactivation Used in Antibody Manufacturing Processes: Effect of Processing Conditions and Biophysical Properties on Antibody Aggregation and Particle Formation". Journal of Pharmaceutical Sciences. 110 (9): 3188–3199. Bibcode:2021JPhmS.110.3188K. doi:10.1016/j.xphs.2021.06.002. ISSN 0022-3549. PMID 34090901.

millipore.com (Global: low place; English: low place)

"Viresolve Process Area Module". Millipore. Retrieved 2010-11-23.
"Optimizing Virus Filter Performance with Prefiltration". Millipore. Retrieved 2010-11-23.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Shander A, Lobel GP, Javidroozi M (June 2016). "Transfusion practices and infectious risks". Expert Review of Hematology. 9 (6): 597–605. doi:10.1586/17474086.2016.1164593. PMID 26959944. S2CID 36732554.
Elveborg S, Monteil V, Mirazimi A (2022-02-19). "Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes". Pathogens. 11 (2): 271. doi:10.3390/pathogens11020271. ISSN 2076-0817. PMC 8879476. PMID 35215213.
Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Güertler L, Ironside JW (January 2016). "Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders". Blood Reviews. 30 (1): 35–48. doi:10.1016/j.blre.2015.07.004. PMC 7115716. PMID 26381318.
Kim NA, Kar S, Li Z, Das TK, Carpenter JF (September 2021). "Mimicking Low pH Virus Inactivation Used in Antibody Manufacturing Processes: Effect of Processing Conditions and Biophysical Properties on Antibody Aggregation and Particle Formation". Journal of Pharmaceutical Sciences. 110 (9): 3188–3199. Bibcode:2021JPhmS.110.3188K. doi:10.1016/j.xphs.2021.06.002. ISSN 0022-3549. PMID 34090901.

ncbi.nlm.nih.gov

Elveborg S, Monteil V, Mirazimi A (2022-02-19). "Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes". Pathogens. 11 (2): 271. doi:10.3390/pathogens11020271. ISSN 2076-0817. PMC 8879476. PMID 35215213.
Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Güertler L, Ironside JW (January 2016). "Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders". Blood Reviews. 30 (1): 35–48. doi:10.1016/j.blre.2015.07.004. PMC 7115716. PMID 26381318.

nybloodcenter.org (Global: low place; English: low place)

"New York Blood Center". Nybloodcenter.org. Archived from the original on 2010-11-24. Retrieved 2010-11-23.

sartorius.com (Global: low place; English: low place)

microsite.sartorius.com

"Sartorius AG Microsites: Virosart". microsite.sartorius.com. Archived from the original on 2016-06-25. Retrieved 2016-05-24.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Shander A, Lobel GP, Javidroozi M (June 2016). "Transfusion practices and infectious risks". Expert Review of Hematology. 9 (6): 597–605. doi:10.1586/17474086.2016.1164593. PMID 26959944. S2CID 36732554.

virology.net (Global: low place; English: low place)

"The Big Picture Book of Viruses - Parvoviruses". Virology.net. Archived from the original on 2010-12-01. Retrieved 2010-11-23.

web.archive.org (Global: 1^st place; English: 1^st place)

"Nanofiltration". Eurodia.com. Archived from the original on 2011-07-10. Retrieved 2010-11-23.
"The Big Picture Book of Viruses - Parvoviruses". Virology.net. Archived from the original on 2010-12-01. Retrieved 2010-11-23.
"Planova: Home". Asahi-kasei.co.jp. 2010-07-29. Archived from the original on 2010-01-29. Retrieved 2010-11-23.
"Sartorius AG Microsites: Virosart". microsite.sartorius.com. Archived from the original on 2016-06-25. Retrieved 2016-05-24.
"New York Blood Center". Nybloodcenter.org. Archived from the original on 2010-11-24. Retrieved 2010-11-23.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Elveborg S, Monteil V, Mirazimi A (2022-02-19). "Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes". Pathogens. 11 (2): 271. doi:10.3390/pathogens11020271. ISSN 2076-0817. PMC 8879476. PMID 35215213.
Kim NA, Kar S, Li Z, Das TK, Carpenter JF (September 2021). "Mimicking Low pH Virus Inactivation Used in Antibody Manufacturing Processes: Effect of Processing Conditions and Biophysical Properties on Antibody Aggregation and Particle Formation". Journal of Pharmaceutical Sciences. 110 (9): 3188–3199. Bibcode:2021JPhmS.110.3188K. doi:10.1016/j.xphs.2021.06.002. ISSN 0022-3549. PMID 34090901.